Successful Kidney-Sparing Systemic Therapy for a High-Risk Ureteral Carcinoma Case.


Journal

Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373

Informations de publication

Date de publication:
2023
Historique:
received: 23 04 2023
accepted: 07 08 2023
medline: 3 11 2023
pubmed: 26 9 2023
entrez: 25 9 2023
Statut: ppublish

Résumé

Upper tract urothelial carcinoma (UTUC) refers to the malignancies located from renal calices toward the end of the ureter and could be classified as renal pelvis carcinoma and ureteral carcinoma. For high-risk UTUC cases with a normal contralateral kidney, radical nephroureterectomy is the standard treatment. As for low-risk UTUC cases or solitary kidney cases, kidney-sparing therapy may be a better choice. Besides, to prevent postoperative recurrence, systemic therapy should be applied, though the investigation is still ongoing. In this case report, we reported a rare case diagnosed with high-risk ureteral carcinoma, but he underwent kidney-sparing therapy due to chronic kidney disease. Recurrence has occurred after segmental ureterectomy. But through the utilization of ablation, bladder instillation, and tislelizumab, endoscopy and CT were normal in the follow-up (the patient refused to take washings from the upper urinary tract) for more than a year. In all, the utilization of ureteroscopic retrograde tumor ablation, BCG bladder instillation, and tislelizumab injection to treat high-risk ureteral carcinoma for kidney-sparing therapy have filled in the gap in this field, which should be promoted to help more patients in similar situations.

Identifiants

pubmed: 37748442
pii: 000533702
doi: 10.1159/000533702
pmc: PMC10623388
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

895-898

Informations de copyright

© 2023 The Author(s). Published by S. Karger AG, Basel.

Références

World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
Surg Oncol. 2011 Mar;20(1):43-55
pubmed: 19854042
RSC Adv. 2020 Jan 8;10(3):1410-1425
pubmed: 35494720
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530
Urol Oncol. 2023 Jun;41(6):295.e19-295.e25
pubmed: 36526526
Investig Clin Urol. 2021 Jul;62(4):389-398
pubmed: 34190434
Transl Androl Urol. 2016 Oct;5(5):636-647
pubmed: 27785420
World J Nephrol. 2016 Mar 6;5(2):158-65
pubmed: 26981440
Curr Oncol Rep. 2022 May;24(5):611-619
pubmed: 35212921
Front Oncol. 2022 Jul 28;12:889028
pubmed: 35965513

Auteurs

Pu Yuan (P)

Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Xinwei Li (X)

Department of Clinical Medicine, Medical College of Zhengzhou University, Zhengzhou, China, 929390403@qq.com.

Yujie Yuan (Y)

Judicial Appraisal Institution, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Peiyuan Xu (P)

Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Hui Wang (H)

Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH